ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.519,38
-0,41%
S&P 500
5.614,56
-2,70%
US Dollar vs BRL
5,8535
-0,02%
Bitcoin
80.362,84
2,41%
Brent Oil
69,345
0,44%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Longeveron Inc (LGVN)

  7. Longeveron Inc (LGVN) Notícias

LGVN

Longeveron (LGVN)

Longeveron Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LGVN
DataHoraFonteTítuloCódigoCompanhia
05/03/202511:25GlobeNewswire Inc.Longeveron® to Present at the 37th Annual Roth ConferenceNASDAQ:LGVNLongeveron Inc
28/02/202518:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGVNLongeveron Inc
28/02/202518:04GlobeNewswire Inc.Longeveron® Announces Full-Year 2024 Financial Results and Provides Business UpdateNASDAQ:LGVNLongeveron Inc
28/02/202518:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LGVNLongeveron Inc
21/02/202510:30GlobeNewswire Inc.Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025NASDAQ:LGVNLongeveron Inc
18/02/202511:25GlobeNewswire Inc.Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™NASDAQ:LGVNLongeveron Inc
06/01/202521:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGVNLongeveron Inc
18/12/202411:10GlobeNewswire Inc.Longeveron to Present at Biotech Showcase 2025NASDAQ:LGVNLongeveron Inc
12/11/202418:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGVNLongeveron Inc
12/11/202418:05GlobeNewswire Inc.Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LGVNLongeveron Inc
11/11/202411:05GlobeNewswire Inc.Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)NASDAQ:LGVNLongeveron Inc
04/11/202418:05GlobeNewswire Inc.Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024NASDAQ:LGVNLongeveron Inc
29/10/202411:00GlobeNewswire Inc.Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)NASDAQ:LGVNLongeveron Inc
27/10/202416:10GlobeNewswire Inc.Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual MeetingNASDAQ:LGVNLongeveron Inc
14/10/202410:05GlobeNewswire Inc.Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)NASDAQ:LGVNLongeveron Inc
09/10/202410:05GlobeNewswire Inc.Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual MeetingNASDAQ:LGVNLongeveron Inc
07/10/202410:05GlobeNewswire Inc.Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy DayNASDAQ:LGVNLongeveron Inc
02/10/202410:05GlobeNewswire Inc.Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceNASDAQ:LGVNLongeveron Inc
26/09/202410:05GlobeNewswire Inc.Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the MesaNASDAQ:LGVNLongeveron Inc
03/09/202410:00GlobeNewswire Inc.Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)NASDAQ:LGVNLongeveron Inc
26/08/202417:05GlobeNewswire Inc.Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:LGVNLongeveron Inc
15/08/202407:08IH Market NewsCisco Beats Estimates and Announces Restructuring, Canoo Rises 6%, Lulus Losses Widen, Latest in EarningsNASDAQ:LGVNLongeveron Inc
14/08/202417:05GlobeNewswire Inc.Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LGVNLongeveron Inc
14/08/202406:58IH Market NewsU.S. Futures Steady After Tuesday’s Strong Recovery; CPI in FocusNASDAQ:LGVNLongeveron Inc
05/08/202417:05GlobeNewswire Inc.Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024NASDAQ:LGVNLongeveron Inc
28/07/202417:51GlobeNewswire Inc.Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)NASDAQ:LGVNLongeveron Inc
19/07/202417:05GlobeNewswire Inc.Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:LGVNLongeveron Inc
18/07/202409:45GlobeNewswire Inc.Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:LGVNLongeveron Inc
17/07/202409:00GlobeNewswire Inc.Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s DiseaseNASDAQ:LGVNLongeveron Inc
10/07/202408:30GlobeNewswire Inc.Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s DiseaseNASDAQ:LGVNLongeveron Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:LGVN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
TPIS3
TRIUNFO PART ON
BOV
TECN3
TECHNOS ON
BOV
PDGR3
PDG REALT ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios